Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
21.16 USD | +1.27% |
|
-0.52% | +86.52% |
06-24 | Harrow, Inc.(NasdaqGM:HROW) added to S&P Pharmaceuticals Select Industry Index | CI |
06-21 | Craig-Hallum Adjusts Price Target on Harrow Health to $30 From $26, Buy Rating Maintained | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+86.52% | 739M | |
+55.32% | 815B | |
+42.66% | 641B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+15.56% | 242B | |
+1.88% | 224B | |
+13.24% | 218B | |
+8.48% | 168B |
- Stock Market
- Equities
- HROW Stock
- News Harrow, Inc.
- B. Riley Lifts Harrow Health's PT to $24 From $22 Accounting for Additional Incremental Revenues From Fab-Five Products, Ramp Up of IHEEZO Sales Trajectory in 2024; Keeps Buy Rating